As a reminder… ABT will obtain a 22% equity stake in new Mylan as consideration for ABT’s existing branded-generics business in Europe, Japan, Canada, Australia, and New Zealand. ABT is retaining its branded-generics business in India, China, Latin America, Russia, and all other emerging markets.
New Mylan will trade under the same ticker (MYL), but the transaction is expected to be a taxable event for MYL shareholders.
ABT plans to monetize its newly obtained MYL shares within the next year or so.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.